HK1003794A1 - Hepatitis b surface antigen formed by recombinant dna techniques vaccines diagnostic cell lines and methods of forming same - Google Patents

Hepatitis b surface antigen formed by recombinant dna techniques vaccines diagnostic cell lines and methods of forming same

Info

Publication number
HK1003794A1
HK1003794A1 HK98103014A HK98103014A HK1003794A1 HK 1003794 A1 HK1003794 A1 HK 1003794A1 HK 98103014 A HK98103014 A HK 98103014A HK 98103014 A HK98103014 A HK 98103014A HK 1003794 A1 HK1003794 A1 HK 1003794A1
Authority
HK
Hong Kong
Prior art keywords
vaccines
hepatitis
methods
cell lines
recombinant dna
Prior art date
Application number
HK98103014A
Other languages
English (en)
Inventor
John S Salstrom
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HK1003794A1 publication Critical patent/HK1003794A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK98103014A 1985-04-15 1998-04-09 Hepatitis b surface antigen formed by recombinant dna techniques vaccines diagnostic cell lines and methods of forming same HK1003794A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP85104521 1985-04-15

Publications (1)

Publication Number Publication Date
HK1003794A1 true HK1003794A1 (en) 1998-11-06

Family

ID=8193449

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103014A HK1003794A1 (en) 1985-04-15 1998-04-09 Hepatitis b surface antigen formed by recombinant dna techniques vaccines diagnostic cell lines and methods of forming same

Country Status (14)

Country Link
EP (2) EP0198474B1 (es)
JP (1) JPS6255088A (es)
CN (1) CN86102640A (es)
AP (1) AP8600035A0 (es)
AT (1) ATE139795T1 (es)
DE (1) DE3650536T2 (es)
ES (1) ES8802440A1 (es)
FI (1) FI861417A0 (es)
HK (1) HK1003794A1 (es)
IE (1) IE75355B1 (es)
IL (1) IL78472A (es)
SG (1) SG43220A1 (es)
YU (1) YU60986A (es)
ZA (1) ZA862797B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPS62236493A (ja) * 1986-04-08 1987-10-16 Green Cross Corp:The ＨＢウイルスのＰｒｅ　Ｓ領域を含むＨＢｓＡｇの製造方法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
CA1341356C (en) * 1987-05-01 2002-04-09 Richard F. Selden Transkaryotic implantation
EP0304578B1 (en) * 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
ES2167304T3 (es) * 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
AU619753B2 (en) * 1987-06-22 1992-02-06 Medeva Holdings B.V. Hepatitis b surface antigen vaccine
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
JPH0216975A (ja) * 1988-02-09 1990-01-19 Eugene Tech Internatl Inc 異成分混交性のプレーｓに富んだｂ型肝炎表面抗原
US6306625B1 (en) 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
CA2026570C (en) * 1989-02-07 2000-05-30 Zeev Even-Chen Method for production and purification of hepatitis b vaccine
JP2957195B2 (ja) * 1989-05-17 1999-10-04 株式会社シノテスト Ｂ型肝炎ウイルス抗体検出システム
US5091300A (en) * 1989-08-03 1992-02-25 Merck & Co., Inc. Radio-immuno assay for hepatitis b virus pres2 antibodies
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
WO1993012815A1 (en) * 1991-12-27 1993-07-08 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis b, antigen and vaccine based on it
ATE168271T1 (de) 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
ES2146231T3 (es) * 1992-07-08 2000-08-01 Innogenetics Nv Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas.
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1059927C (zh) * 1994-03-10 2000-12-27 中国科学院上海生物化学研究所 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白
US6100043A (en) * 1995-08-04 2000-08-08 The Perkin-Elmer Corporation Recombinant clone selection system
US5843656A (en) * 1995-08-07 1998-12-01 The Perkin-Elmer Corporation Recombinant clone selection system
AU6844696A (en) * 1995-08-07 1997-03-05 Perkin-Elmer Corporation, The Recombinant clone selection system
CN1067721C (zh) * 1996-07-04 2001-06-27 中国科学院上海生物化学研究所 含前表面抗原1和2免疫决定簇的乙肝表面抗原
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
ES2359473T3 (es) 2003-07-21 2011-05-23 Transgene S.A. Citoquinas multifuncionales.
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL2066344T3 (pl) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20100183667A1 (en) 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
US20200377606A1 (en) 2016-04-18 2020-12-03 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
KR20220165789A (ko) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3976092A1 (en) 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN111961664A (zh) * 2020-09-08 2020-11-20 武汉中投汉嘉科技有限公司 一种核酸提取液
WO2022217019A1 (en) 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD147855A5 (de) * 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
EP0094428B1 (en) * 1981-11-23 1992-02-12 University Patents, Inc. Control of dna sequence transcription
WO1984002534A1 (en) * 1982-12-23 1984-07-05 Us Commerce Human growth hormone produced by recombinant dna in mouse cells
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues

Also Published As

Publication number Publication date
ATE139795T1 (de) 1996-07-15
IE75355B1 (en) 1997-08-27
ES8802440A1 (es) 1988-06-01
EP0719863A1 (en) 1996-07-03
JPS6255088A (ja) 1987-03-10
FI861417A0 (fi) 1986-04-01
IL78472A (en) 2004-08-31
EP0198474A1 (en) 1986-10-22
DE3650536T2 (de) 1997-02-27
AP8600035A0 (en) 1987-10-14
EP0198474B1 (en) 1996-06-26
DE3650536D1 (de) 1996-08-01
CN86102640A (zh) 1987-04-08
ZA862797B (en) 1988-04-27
ES553953A0 (es) 1988-06-01
YU60986A (en) 1988-10-31
IE860965L (en) 1986-10-15
IL78472A0 (en) 1986-08-31
SG43220A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
HK1003794A1 (en) Hepatitis b surface antigen formed by recombinant dna techniques vaccines diagnostic cell lines and methods of forming same
ZA88488B (en) Hepatitis b virus surface antigens and hybrid antigens containing them
LV10726A (lv) Hepatita C virusa diagnostikas lidzekli un vakcinas
PH25249A (en) Method for producing hepatitis b virus proteins in yeast
EP0185494A3 (en) Detection of specific sequences in nucleic acids
IL69423A0 (en) Recombinant plasmid inserted with hepatitis b virus gene,yeast transformed with said recombinant plasmid and production of hepatitis b virus surface antigen
ZA862812B (en) Antigens related to envelope glycoprotein of the virus of aids,methods of obtaining these antigens and means employed in these methods
GB8712936D0 (en) Induction of gene expression in yeast
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
EP0287030A3 (en) Immunological methods and materials for detection of tumor associated antigens
EP0232410A4 (en) CLEAVAGE PROCESS AND BUFFER FOR THE EXTRACTION OF HEPATITIS B SURFACE ANTIGENS FROM YEAR CELLS.
IL72452A0 (en) Method for the preparation of yeast chromatin and its use for obtaining antibodies for the detection of mammalian carcinomas
GB2068970B (en) Recombinant dna technique for the preparation of a protein resembling human interferon
JPS54141790A (en) Modified dna and method of manufacturing hybrid protein using it
OA08238A (en) Hepatitis B surface antigen formed by recombinant DNA techniques vaccines diagnostics cell lines and methods of forming same
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
IL83670A0 (en) Dna coding for antigen protein of rinderpest virus and process for the preparation thereof
ZA868612B (en) Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
FI914267A0 (fi) Diagnostiset menetelmät ja määrityssarjat, joissa käytetään yhdistelmä-DNA-tekniikalla muodostettua hepatitis B -viruksen pinta-antigeenia
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
IE852110L (en) Recombinant hepatitis antigen
ZA869516B (en) Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
ZA874498B (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)